clinical trial · NCT07020819
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Guillain-Barre SyndromeTanruprubart
brief summary
The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.
started
Sep 12, 2025
primary completion
May 31, 2027
completion
Jun 30, 2028
last updated
Oct 26, 2026
official title
An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of ANX005 in Participants With Guillain-Barré Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol